Contributory Negligence of a Minor As a Matter of Law in Missouri

With respect to the degree of care which must be exercised by a child, for purposes of determining whether lie is guilty of negligence or contributory negligence, the general rule is stated that he must conform to that standard of conduct to be expected of a child of similar age, experience and intelligence. While it may be said that the courts of Missouri are generally in accord with this rule, the cases have varied widely in the application thereof. As a matter of fact, it has been admitted by the Supreme Court of Missouri that the Missouri cases involving the issue of contributory negligence of a minor as a matter of law are in irreconcilable conflict.” With this in mind, the maxim that each case must be decided upon its own facts seems particularly appropriate to the determination of whether a minor has, in a given case, been contributorily negligent as a matter of law. However, to facilitate analysis of the Missouri cases, they should be classified at least according to the general types of factual situations involved therein. This Article will attempt to make such an analysis, and, to that end, will be based upon a classification involving the following four general categories: (1) Cases involving minors who were injured in rail crossing accidents; (2) Attractive nuisance cases; (3) Cases in which minors were injured as a result of their employment, usually while operating machinery; and (4) Cases where minors and adults were injured while in the attempt to alight from public carriers

A numerical and experimental study of the response of selected compression-loaded composite shells with cutouts

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/76998/1/AIAA-1998-1988-596.pd

The response of composite cylindrical shells with cutouts and subjected to internal pressure and axial compression loads

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/76299/1/AIAA-1998-1768-190.pd

1952: Abilene Christian College Bible Lectures - Full Text

Delivered in the Auditorium of Abilene Christian College, February, 1952 ABILENE, TEXAS PRICE, $3.00 firm foundation publishing house Box 77 Austin Cl, Texa

Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease

AbstractObjective: Vascular endothelial growth factor and basic fibroblast growth factor are potent stimulators of angiogenesis. Children with cyanotic congenital heart disease often experience the development of widespread formation of collateral blood vessels, which may represent a form of abnormal angiogenesis. We undertook the present study to determine whether children with cyanotic congenital heart disease have elevated serum levels of vascular endothelial growth factor and basic fibroblast growth factor. Methods: Serum was obtained from 22 children with cyanotic congenital heart disease and 19 children with acyanotic heart disease during cardiac catheterization. Samples were taken from the superior vena cava, inferior vena cava, and a systemic artery. Vascular endothelial growth factor and basic fibroblast growth factor levels were measured in the serum from each of these sites by enzyme–linked immunosorbent assay. Results: Vascular endothelial growth factor was significantly elevated in the superior vena cava (P = .04) and systemic artery (P = .02) but not in the inferior vena cava (P = .2) of children with cyanotic congenital heart disease compared to children with acyanotic heart disease. The mean vascular endothelial growth factor level, determined by averaging the means of all 3 sites, was also significantly elevated (P = .03). Basic fibroblast growth factor was only significantly elevated in the systemic artery (P = .02). Conclusion: Children with cyanotic congenital heart disease have elevated systemic levels of vascular endothelial growth factor. These findings suggest that the widespread formation of collateral vessels in these children may be mediated by vascular endothelial growth factor. (J Thorac Cardiovasc Surg 2000;119:534-9

1928-29: Abilene Christian College Bible Lectures - Full Text

INTRODUCTION It has been the custom of Abilene Christian College for several years to hold an annual “Lectureship” the last week in February. This is a time of gathering of brethren from all over the state and adjoining states. It is a time of a great spiritual feast. It affords an opportunity for brethren to meet and talk over the work of the Lord. It also enables us to hear again great men of God whose voices have sounded the Word of the Lord in the days of the past in great meetings. In order that those who are not permitted to hear the lectures may enjoy them it has been the custom of Abilene Christian College to publish the lectures in a book at the end of each two years. We feel that these wonderful messages from some of the greatest minds of the church ought to be preserved that they may do good even after the lips of the speakers have become silent. It is with a prayer that great good may come that this volume of lectures of 1928 and 1929 is sent forth. We regret that some of the lectures could not be included in the book. Several of the brethren neglected to send in their manuscripts; some other manuscripts were destroyed by fire, and the brethren did not replace them. Most\u27 of the lectures are in the book. BATSELL BAXTER. DELIVERED IN THE AUDITORIUM OF ABILENE CHRISTIAN COLLEGE ABILENE, TEXAS FEBRUARY 1928-1929 FIRM FOUNDATION PUBLISHING HOUSE 104-106-108 E. 9th Street Austin, Texas

1940: Abilene Christian College Bible Lectures - Full Text

Delivered in the Auditorium of Abilene Christian College, February, 1940, Abilene, Texas. Published April, 1940 PRICE, $1.00 FIRM FOUNDATION PUBLISHING HOUSE Austin, Texas

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed